PDS Biotechnology (PDSB) Amortization of Deferred Charges (2015 - 2023)
PDS Biotechnology's (PDSB) quarterly Amortization of Deferred Charges came in at $40171.0 in Q3 2023, down 33.33% YoY from $60258.0 in Q3 2022, and down 33.33% on a QoQ basis from $60257.0 in Q2 2023.
PDS Biotechnology (PDSB) Amortization of Deferred Charges (2015 - 2023) Analysis & Trends
PDS Biotechnology (PDSB) has 8 years of Amortization of Deferred Charges data on file, last reported at $40171.0 in Q3 2023.
- Quarterly Amortization of Deferred Charges fell 33.33% year-over-year to $40171.0 in Q3 2023, while the trailing twelve-month figure through Jun 2024 was $40171.0 (down 83.33% YoY) and the FY2023 annual result came in at $160685.0, down 33.33% from the prior year.
- Amortization of Deferred Charges slipped to $40171.0 in Q3 2023, from $60257.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $65149.0 in Q3 2020 to a low of $40171.0 in Q3 2023.
- A 4-year average of $57387.8 and a median of $60257.0 in 2021 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2021 — Amortization of Deferred Charges jumped 44.16% — and 2023, when it tumbled 33.33%.
- Tracing PDSB's Amortization of Deferred Charges over 4 years: stood at $53735.0 in 2020, then advanced by 12.14% to $60256.0 in 2021, then gained by 0.0% to $60257.0 in 2022, then tumbled by 33.33% to $40171.0 in 2023.
- The last three Amortization of Deferred Charges figures came in at $40171.0 (Q3 2023), $60257.0 (Q2 2023), and $60257.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 40,171.00 |
| Sep 30, 2023 | 40,171.00 |
| Jun 30, 2023 | 60,257.00 |
| Jun 30, 2023 | 60,257.00 |
| Mar 31, 2023 | 60,257.00 |
| Mar 31, 2023 | 60,257.00 |
| Dec 31, 2022 | 60,257.00 |
| Dec 31, 2022 | 60,257.00 |
| Sep 30, 2022 | 60,258.00 |
| Sep 30, 2022 | 60,258.00 |
| Jun 30, 2022 | 60,257.00 |
| Jun 30, 2022 | 60,257.00 |
| Mar 31, 2022 | 60,257.00 |
| Mar 31, 2022 | 60,257.00 |
| Dec 31, 2021 | 60,256.00 |
| Dec 31, 2021 | 60,256.00 |
| Sep 30, 2021 | 60,261.00 |
| Sep 30, 2021 | 60,261.00 |
| Jun 30, 2021 | 60,257.00 |
| Jun 30, 2021 | 60,257.00 |